Veracyte Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Veracyte Inc 公司

Veracyte, Inc. 是一家全球诊断公司。该公司为临床医生提供指导和保证患者所需的见解。该公司提供针对甲状腺癌 (Afirma)、前列腺癌 (Decipher Prostate)、乳腺癌 (Prosigna)、间质性肺病 (Envisia) 和膀胱癌 (Decipher Bladder) 的检测。其 Percepta 鼻拭子检测正在其临床实验室改进修正案 (CLIA) 实验室中进行，以支持临床研究，其针对肾癌和淋巴瘤的检测正在开发中，后者作为伴随诊断。其产品包括 Prosigna 乳腺癌检测、nCounter 分析系统、相关诊断试剂盒和服务。在美国，该公司通过位于加利福尼亚州南旧金山和圣地亚哥的 CLIA 实验室提供实验室开发的检测 (LDT)，并由位于德克萨斯州奥斯汀的细胞病理学专业知识提供支持。该公司还提供全基因组 MRD 平台，使其能够进行早期癌症诊断和风险评估。

公司简介

公司代码VCYT

公司名称Veracyte Inc

上市日期Oct 30, 2013

CEOMr. Marc A. Stapley

员工数量824

证券类型Ordinary Share

年结日Oct 30

公司地址6000 Shoreline Court, Suite 300

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ Global Market Consolidated

国家United States of America

邮编94080

电话16502436300

网址https://www.veracyte.com/

公司代码VCYT

上市日期Oct 30, 2013

CEOMr. Marc A. Stapley

公司高管

名称

名称/职务

职务

持股

持股变动

Mr. Marc A. Stapley

Chief Executive Officer, Director

100.93K

-13.37%

Dr. Robert S. (Rob) Epstein, M.D.

Independent Chairman of the Board

62.45K

+17.55%

Dr. Eliav Barr, M.D.

Independent Director

32.81K

+39.68%

Mr. Evan Jones

Independent Director

32.19K

+40.76%

Ms. Rebecca Chambers

Chief Financial Officer

27.97K

-16.11%

Ms. Muna Bhanji

Independent Director

27.84K

+20.48%

Mr. Jens Holstein

Independent Director

25.73K

+56.82%

Ms. Karin Eastham, CPA

Independent Director

11.76K

+67.35%

Dr. Phillip G. (Phil) Febbo, M.D.

Chief Scientific Officer, Chief Medical Officer

10.14K

-22.57%

Ms. Annie Mcguire

Chief Human Resources Officer, General Counsel

6.68K

-34.42%

名称

名称/职务

职务

持股

持股变动

Mr. Marc A. Stapley

Chief Executive Officer, Director

100.93K

-13.37%

Dr. Robert S. (Rob) Epstein, M.D.

Independent Chairman of the Board

62.45K

+17.55%

Dr. Eliav Barr, M.D.

Independent Director

32.81K

+39.68%

Mr. Evan Jones

Independent Director

32.19K

+40.76%

Ms. Rebecca Chambers

Chief Financial Officer

27.97K

-16.11%

Ms. Muna Bhanji

Independent Director

27.84K

+20.48%

收入明细

单位: USD更新时间: 7月6日周日

FY2024

FY2023

FY2022

FY2021

FY2020

暂无数据

地区USD

名称

营收

占比

United States

423.54M

95.01%

International

22.23M

4.99%

业务

地区

暂无数据

股东统计

更新时间: 8月15日周五

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

10.27%

Fidelity Management & Research Company LLC

8.81%

Artisan Partners Limited Partnership

8.04%

BlackRock Institutional Trust Company, N.A.

7.78%

ARK Investment Management LLC

4.83%

其他

60.27%

持股股东

占比

The Vanguard Group, Inc.

10.27%

Fidelity Management & Research Company LLC

8.81%

Artisan Partners Limited Partnership

8.04%

BlackRock Institutional Trust Company, N.A.

7.78%

ARK Investment Management LLC

4.83%

其他

60.27%

股东类型

持股股东

占比

Investment Advisor

62.40%

Investment Advisor/Hedge Fund

35.53%

Hedge Fund

7.02%

Research Firm

2.75%

Pension Fund

1.33%

Individual Investor

0.56%

Bank and Trust

0.43%

Sovereign Wealth Fund

0.06%

Insurance Company

0.04%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

598

84.22M

107.53%

-1.90M

2025Q1

612

85.86M

109.67%

-679.43K

2024Q4

593

81.64M

104.75%

-2.62M

2024Q3

567

81.88M

106.62%

-2.30M

2024Q2

533

81.65M

106.83%

-3.86M

2024Q1

532

81.30M

103.75%

+1.22M

2023Q4

524

76.49M

104.40%

-3.87M

2023Q3

520

77.05M

105.90%

-3.78M

2023Q2

516

77.28M

106.70%

-4.52M

2023Q1

533

77.62M

107.25%

-6.79M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

8.25M

10.53%

+52.03K

+0.64%

Mar 31, 2025

Fidelity Management & Research Company LLC

6.17M

7.88%

+4.15M

+205.06%

Mar 31, 2025

Artisan Partners Limited Partnership

5.24M

6.69%

-1.36M

-20.60%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.21M

7.92%

-41.84K

-0.67%

Mar 31, 2025

ARK Investment Management LLC

3.21M

4.09%

-286.15K

-8.20%

May 31, 2025

Wellington Management Company, LLP

3.85M

4.92%

-231.44K

-5.67%

Mar 31, 2025

State Street Global Advisors (US)

3.16M

4.03%

+247.55K

+8.50%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.91M

3.72%

+28.17K

+0.98%

Mar 31, 2025

ArrowMark Colorado Holdings, LLC

3.23M

4.12%

+146.65K

+4.76%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.93M

2.47%

+94.91K

+5.16%

Mar 31, 2025

持股ETF

更新时间: 9月2日周二

机构名称

占比

First Trust NYSE Arca Biotechnology Index Fund

2.99%

ARK Genomic Revolution ETF

2.7%

Invesco Biotechnology & Genome ETF

2.29%

Global X Genomics & Biotechnology ETF

2.23%

WisdomTree BioRevolution Fund

1.57%

Invesco S&P SmallCap Health Care ETF

1.24%

ROBO Global Healthcare Technology & Innovation ETF

1.19%

ARK Innovation ETF

1.16%

ROBO Global Artificial Intelligence ETF

1.14%

Invesco S&P SmallCap 600 Pure Growth ETF

1.05%

First Trust NYSE Arca Biotechnology Index Fund

占比2.99%

ARK Genomic Revolution ETF

占比2.7%

Invesco Biotechnology & Genome ETF

占比2.29%

Global X Genomics & Biotechnology ETF

占比2.23%

WisdomTree BioRevolution Fund

占比1.57%

Invesco S&P SmallCap Health Care ETF

占比1.24%

ROBO Global Healthcare Technology & Innovation ETF

占比1.19%

ARK Innovation ETF

占比1.16%

ROBO Global Artificial Intelligence ETF

占比1.14%

Invesco S&P SmallCap 600 Pure Growth ETF

占比1.05%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

Veracyte Inc

34.110USD

Veracyte Inc

34.110

概览

公司

财务

分析